Author + information
- Received May 13, 2009
- Revision received June 22, 2009
- Accepted June 29, 2009
- Published online January 12, 2010.
- Muhammed Z. Khawaja, MBBS*,* (, )
- Peter Haworth, MBBS*,
- Azad Ghuran, MBChB, MD*,
- Lorraine Lee, BSE*,
- Adam de Belder, MD*,
- Neville Hutchinson, MD*,
- Uday Trivedi, MBBS*,
- Jean-Claude Laborde, MD† and
- David Hildick-Smith, MD*
- ↵*Reprint requests and correspondence:
Dr. Muhammed Z. Khawaja, Specialist Registrar in Cardiology, Sussex Cardiac Centre, Brighton & Sussex University Hospitals NHS Trust, Eastern Road, Brighton, East Sussex BN2 5BE, United Kingdom
Transcatheter aortic valve implantation is increasingly being used to treat severe aortic stenosis in patients with high operative risk. In an aging population the incidence of aortic stenosis is rising, and increasing numbers of elderly patients are undergoing aortic valve replacement with bioprosthetic valves. Therefore, there is a corresponding increase in prosthetic degeneration. This presents cardiologists with a cohort of patients for whom the risk of re-do aortic valve surgery is prohibitive. We present the first series of such patients with degenerative bioprosthetic stenosis or regurgitation successfully treated with CoreValve (Medtronic, Luxembourg) implantation.
Dr. Laborde is a consultant and employee for CoreValve. Dr. Hildick-Smith is a proctor for CoreValve (Medtronic, Minneapolis, Minnesota).
- Received May 13, 2009.
- Revision received June 22, 2009.
- Accepted June 29, 2009.
- American College of Cardiology Foundation